Hutchison China MediTech Limited (HCM) Earns Coverage Optimism Rating of 0.10

Media stories about Hutchison China MediTech Limited (NASDAQ:HCM) have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Hutchison China MediTech Limited earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.1081935633701 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

A number of equities research analysts have recently commented on HCM shares. Canaccord Genuity set a $30.00 price objective on Hutchison China MediTech Limited and gave the company a “buy” rating in a research report on Monday, July 31st. BidaskClub raised Hutchison China MediTech Limited from a “hold” rating to a “buy” rating in a research report on Wednesday, September 6th.

Shares of Hutchison China MediTech Limited (NASDAQ HCM) traded down $0.93 during trading hours on Tuesday, hitting $34.22. The stock had a trading volume of 49,900 shares, compared to its average volume of 45,871. The company has a quick ratio of 1.73, a current ratio of 1.84 and a debt-to-equity ratio of 0.09. Hutchison China MediTech Limited has a twelve month low of $12.19 and a twelve month high of $36.32.

COPYRIGHT VIOLATION NOTICE: “Hutchison China MediTech Limited (HCM) Earns Coverage Optimism Rating of 0.10” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://sportsperspectives.com/2017/11/21/hutchison-china-meditech-limited-hcm-earns-coverage-optimism-rating-of-0-10.html.

About Hutchison China MediTech Limited

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

Insider Buying and Selling by Quarter for Hutchison China MediTech Limited (NASDAQ:HCM)

Receive News & Ratings for Hutchison China MediTech Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply